SPRC Live signaler | Maksimer profitt med Getagraph.com

SELG 121247 min ago

@ $3.99

Utstedt: 6 feb 2024 @ 15:45

Avkastning: -65.41%

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 21:31):

Stats
Dagens volum	182 656
Gjennomsnittsvolum	833 000
Markedsverdi	3.38M
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00900 (0.65%)

Volum Korrelasjon

Lang: -0.04 (neutral)

Kort: -0.42 (neutral)

Signal:(42.756) Neutral

SciSparc Ltd. Korrelasjon

10 Mest positive korrelasjoner
MXIM	0.937
HYMC	0.83
LSBK	0.801

10 Mest negative korrelasjoner
IKNX	-0.851
APOP	-0.841
CMLF	-0.826
MAGS	-0.805
MOSY	-0.804

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

SciSparc Ltd. Korrelasjon - Valuta/Råvare

-0.03
( neutral )

-0.11
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.71
( moderate negative )

0.14
( neutral )

SciSparc Ltd. Økonomi

Annual	2023
Omsetning:	$2.88M
Bruttogevinst:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2023
Omsetning:	$2.88M
Bruttogevinst:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2022
Omsetning:	$1.35M
Bruttogevinst:	$1.03M (76.10 %)
EPS:	$-14.73

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.